Ashwin V. Kammula

Ashwin V. Kammula

Auto-generated profile, based on publicly available information

Ashwin V. Kammula

Broad Institute of MIT and Harvard, Cambridge, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2023 in Nature
Verified
Journal Article
Open access
PDF file
CBChristina K. Baumgartner
Christina K. Baumgartner
HEHakimeh Ebrahimi-Nik
Hakimeh Ebrahimi-Nik
AIArvin Iracheta-Vellve
Arvin Iracheta-Vellve
KHKeith M. Hamel
Keith M. Hamel
KOKira E. Olander
Kira E. Olander
RMRobert T. Manguso
Robert T. Manguso
Immune checkpoint blockade is effective for some patients with cancer, but most are refractory to current immunotherapies and new approaches are needed to overcome resistance1,2. The protein tyrosine phosphatases PTPN2 and PTPN1 are central regulators of inflammation, and their genetic deletion in either tumour cells or immune cells promotes anti-tumour immunity3–6. However, phosphatases are challenging drug targets; in particular, the active site has been considered undruggable. Here we present the discovery and characterization of ABBV-CLS-484 (AC484), a first-in-class, orally bioavailable, potent PTPN2 and PTPN1 active-site inhibitor. AC484 treatment in vitro amplifies the response to interferon and promotes the activation and function of several immune cell subsets. In mouse models of cancer resistant to PD-1 blockade, AC484 monotherapy generates potent anti-tumour immunity. We show that AC484 inflames the tumour microenvironment and promotes natural killer cell and CD8+ T cell function by enhancing JAK–STAT signalling and reducing T cell dysfunction. Inhibitors of PTPN2 and PTPN1 offer a promising new strategy for cancer immunotherapy and are currently being evaluated in patients with advanced solid tumours (ClinicalTrials.gov identifier NCT04777994). More broadly, our study shows that small-molecule inhibitors of key intracellular immune regulators can achieve efficacy comparable to or exceeding that of antibody-based immune checkpoint blockade in preclinical models. Finally, to our knowledge, AC484 represents the first active-site phosphatase inhibitor to enter clinical evaluation for cancer immunotherapy and may pave the way for additional therapeutics that target this important class of enzymes.

18 April 2024 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
SSSanju Sinha
Sanju Sinha
RVRahulsimham Vegesna
Rahulsimham Vegesna
Sumit MukherjeeSumit Mukherjee
Sumit Mukherjee
AKAshwin V. Kammula
Ashwin V. Kammula
SDSaugato Rahman Dhruba
Saugato Rahman Dhruba
EREytan Ruppin
Eytan Ruppin

12 July 2024 in Science
Verified
Journal Article
Closed access
MWMeng-Ju Wu
Meng-Ju Wu
HKHiroshi Kondo
Hiroshi Kondo
AKAshwin V. Kammula
Ashwin V. Kammula
LSLei Shi
Lei Shi
YXYi Xiao
Yi Xiao
NBNabeel Bardeesy
Nabeel Bardeesy
Isocitrate dehydrogenase 1 ( IDH1 ) is the most commonly mutated metabolic gene across human cancers. Mutant IDH1 (mIDH1) generates the oncometabolite (R)-2-hydroxyglutarate, disrupting enzymes involved in epigenetics and other processes. A hallmark of IDH1 -mutant solid tumors is T cell exclusion, whereas mIDH1 inhibition in preclinical models restores antitumor immunity. Here, we define a cell-autonomous mechanism of mIDH1-driven immune evasion. IDH1 -mutant solid tumors show selective hypermethylation and silencing of the cytoplasmic double-stranded DNA (dsDNA) sensor CGAS , compromising innate immune signaling. mIDH1 inhibition restores DNA demethylation, derepressing CGAS and transposable element (TE) subclasses. dsDNA produced by TE-reverse transcriptase (TE-RT) activates cGAS, triggering viral mimicry and stimulating antitumor immunity. In summary, we demonstrate that mIDH1 epigenetically suppresses innate immunity and link endogenous RT activity to the mechanism of action of a US Food and Drug Administration–approved oncology drug.

23 March 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
AKAshwin V. Kammula
Ashwin V. Kammula
ASAlejandro A. Schäffer
Alejandro A. Schäffer
PRPadma Sheila Rajagopal
Padma Sheila Rajagopal
RKRazelle Kurzrock
Razelle Kurzrock
EREytan Ruppin
Eytan Ruppin
Identifying sex differences in outcomes and toxicity between males and females in oncology clinical trials is important and has also been mandated by National Institutes of Health policies. Here we analyze the Trialtrove database, finding that, strikingly, only 472/89,221 oncology clinical trials (0.5%) had curated post-treatment sex comparisons. Among 288 trials with comparisons of survival, outcome, or response, 16% report males having statistically significant better survival outcome or response, while 42% reported significantly better survival outcome or response for females. The strongest differences are in trials of EGFR inhibitors in lung cancer and rituximab in non-Hodgkin’s lymphoma (both favoring females). Among 44 trials with side effect comparisons, more trials report significantly lesser side effects in males (N = 22) than in females (N = 13). Thus, while statistical comparisons between sexes in oncology trials are rarely reported, important differences in outcome and toxicity exist. These considerable outcome and toxicity differences highlight the need for reporting sex differences more thoroughly going forward.

27 September 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
IGIlaria Gritti
Ilaria Gritti
JWJinkai Wan
Jinkai Wan
VWVajira Weeresekara
Vajira Weeresekara
JVJoel M. Vaz
Joel M. Vaz
GTGiuseppe Tarantino
Giuseppe Tarantino
NBNabeel Bardeesy
Nabeel Bardeesy
Fibrolamellar carcinoma (FLC) is a liver cancer of adolescents and young adults characterized by fusions of the genes encoding the protein kinase A catalytic subunit, PRKACA, and heat shock protein, DNAJB1. The chimeric DNAJB1-PRKACA protein has increased kinase activity and is essential for FLC xenograft growth. Here, we explore the critical oncogenic pathways controlled by DNAJB1-PRKACA using patient-derived FLC models, engineered systems, and patient samples. We show that a core function of DNAJB1-PRKACA is the phosphorylation and inactivation of salt-inducible kinases (SIKs). This leads to deregulation of the CRTC2 transcriptional coactivator and p300 acetyltransferase, resulting in transcriptional reprogramming and increased global histone acetylation, driving malignant growth. Our studies establish a central oncogenic mechanism of DNAJB1-PRKACA and suggest the potential of targeting CRTC2/p300 in FLC. Notably, these findings link this rare cancer’s signature fusion oncoprotein to more common cancer gene alterations involving STK11 and GNAS, which also function via SIK suppression. Significance: This work combines functional studies in model systems and examination of human tumor specimens to define a central oncogenic pathway driven by DNAJB1-PRKACA fusions in FLC. DNAJB1-PRKACA-mediated inactivation of the SIK stimulates CRTC2-p300-mediated transcription to drive tumor growth. The findings illuminate pathogenic mechanisms and inform therapeutic development.

9 April 2026 in Science
Verified
Journal Article
Closed access
JCJooho Chung
Jooho Chung
MVMounica Vallurupalli
Mounica Vallurupalli
SNSarah Noel
Sarah Noel
GSGail Schor
Gail Schor
SMSofia Mrowka
Sofia Mrowka
RMRobert T. Manguso
Robert T. Manguso
Macrophages exert antitumorigenic activity through phagocytosis, but phagocytosis-enhancing therapeutics have not improved acute myeloid leukemia (AML) outcomes. To identify phagocytosis regulators, we performed CRISPR knockout screens in human AML cells cocultured with human macrophages. We found that the “don’t eat me” signal CD47 inhibited mouse but not human macrophage phagocytosis. However, O-linked glycosylation and sialylation were strong negative regulators of phagocytosis. In AML, the cell surface mucin-like glycoprotein CD43 was the major effector of these pathways. Inhibition of phagocytosis by CD43 was dependent on the length of its ectodomain and independent of the macrophage sialic acid receptors SIGLEC-1, SIGLEC-7, and SIGLEC-9. The inhibitory effects of CD43 extended beyond human macrophages to natural killer and T cells. Thus, CD43 forms a glyco-immune barrier that restrains both innate and adaptive antileukemic immunity.